Compare stocks

Saniona AB is a biopharmaceutical company based in Sweden, focusing on the discovery and development of treatments for rare diseases of the central nervous system. Its core business involves the research and development of ion channel modulators, which are pivotal in influencing cellular activity and treating neurological disorders. Saniona's pipeline includes product candidates such as Tesomet for rare eating disorders and SAN711 for neuropathic pain disorders. The company leverages its proprietary ion channel drug discovery platform to enhance its development capabilities. Saniona's strategic approach is distinguished by its focus on niche medical conditions with high unmet needs, positioning itself uniquely within the pharmaceutical industry. Sources: Saniona official website and public disclosures.

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.